Immuron Ltd Asset Resilience Ratio
Immuron Ltd asset resilience ratio. Immuron Ltd (IMC) has an Asset Resilience Ratio of 29.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immuron Ltd (2000–2025)
Asset resilience ratio of Immuron Ltd from 2000 to 2025. This chart shows how Immuron Ltd's Asset Resilience Ratio has changed over time. Read IMC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immuron Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Immuron Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.04 Million | 29.97% |
| Total Liquid Assets | AU$3.04 Million | 29.97% |
Asset Resilience Insights
- Very High Liquidity: Immuron Ltd maintains exceptional liquid asset reserves at 29.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immuron Ltd Industry Peers by Asset Resilience Ratio
Compare Immuron Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Immuron Ltd Asset Resilience Ratio by Year (2000–2025)
Immuron Ltd asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Immuron Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 29.97% | AU$3.04 Million ≈ $2.15 Million |
AU$10.13 Million ≈ $7.17 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.55 Million ≈ $11.00 Million |
-- |
| 2023-06-30 | 8.34% | AU$1.83 Million ≈ $1.30 Million |
AU$21.99 Million ≈ $15.56 Million |
+0.96pp |
| 2022-06-30 | 7.38% | AU$1.83 Million ≈ $1.30 Million |
AU$24.86 Million ≈ $17.59 Million |
-43.77pp |
| 2018-06-30 | 51.15% | AU$4.73 Million ≈ $3.34 Million |
AU$9.24 Million ≈ $6.54 Million |
+2.94pp |
| 2017-06-30 | 48.21% | AU$3.99 Million ≈ $2.83 Million |
AU$8.29 Million ≈ $5.86 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$8.83 Million ≈ $6.25 Million |
-- |
| 2006-06-30 | 16.60% | AU$1.10 Million ≈ $778.32K |
AU$6.63 Million ≈ $4.69 Million |
-26.59pp |
| 2005-06-30 | 43.19% | AU$3.48 Million ≈ $2.46 Million |
AU$8.05 Million ≈ $5.70 Million |
+22.83pp |
| 2004-06-30 | 20.37% | AU$1.00 Million ≈ $707.56K |
AU$4.91 Million ≈ $3.47 Million |
-15.40pp |
| 2003-06-30 | 35.77% | AU$2.13 Million ≈ $1.51 Million |
AU$5.96 Million ≈ $4.21 Million |
-6.81pp |
| 2002-06-30 | 42.57% | AU$2.80 Million ≈ $1.98 Million |
AU$6.58 Million ≈ $4.65 Million |
-15.35pp |
| 2001-06-30 | 57.92% | AU$4.54 Million ≈ $3.21 Million |
AU$7.83 Million ≈ $5.54 Million |
-30.91pp |
| 2000-06-30 | 88.83% | AU$4.00 Million ≈ $2.83 Million |
AU$4.50 Million ≈ $3.19 Million |
-- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more